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to help exclude the diagnosis of DVT. Although initial
results were promising, more current studies indicate that
there is significant variability in the sensitivity and negative
predictive values of the different D-dimer assays that are
currently available.4,5 Low sensitivity and negative predic-
tive values result in unacceptably high false-negative rates,
leading to underdiagnosis. The newer, rapid enzyme-linked
immunosorbent assays (ELISAs) have higher sensitivity and
negative predictive values.4,5 However, they are significantly
more expensive than either latex assays or SimpliRED
(Agen Biomedical Ltd, Acacia Ridge, Australia).
Most recently, clinical models to predict pretest prob-
ability (PTP) of DVT have been developed and evaluated
for their usefulness to exclude the diagnosis of DVT and
limit unnecessary VDI.6 In addition, the clinical use of
combined assessment schemes that incorporate PTP, D-
dimer, and/or venous impedence plethysmography has
been demonstrated.7-9 The objective of our investigation
was to evaluate the efficacy and cost-effectiveness of a
DVT screening protocol consisting of global PTP, selec-
tive D-dimer assay (SimpliRED), and selective VDI to
exclude the diagnosis of DVT among emergency depart-
ment (ED) patients.
METHODS
This was a prospective study of all patients with sus-
pected DVT referred from the ED at a university-affili-
ated hospital to the in-hospital vascular laboratory
Deep venous thrombosis (DVT), the third most com-
mon cardiovascular disorder in the United States, occurs
in 1% of the population annually.1 Complications associ-
ated with DVT can be potentially fatal if the condition
remains unrecognized and untreated. Unfortunately, the
symptoms of DVT are not specific; thus, the clinical exam-
ination alone is insufficient to establish the diagnosis. In
the past decade, noninvasive venous duplex imaging
(VDI) has become the diagnostic test of choice to evalu-
ate DVT. However, nonselective use of VDI resulting in
low diagnostic yield is both expensive and time consum-
ing. Previous studies have indicated that DVT is con-
firmed in only 25% of patients referred to vascular
laboratories for VDI.2,3
In recent years, several authors have evaluated the role
of D-dimer assay as an adjunct to the clinical examination
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Objective: The purpose of this study was to evaluate the efficacy and cost effectiveness of a deep venous thrombosis
(DVT) screening protocol incorporating DVT pretest probability (PTP), selective D-dimer assay, and venous duplex
imaging (VDI) to exclude the diagnosis of DVT among emergency department (ED) patients.
Methods: A prospective study of all patients evaluated in the ED for suspected DVT during 1 year was undertaken.
Patients were classified into PTP risk category by ED physicians before VDI. Correlation studies were completed using
VDI as the gold standard. Charges associated with the protocol were calculated.
Results: One hundred fourteen patients were included. The incidence of DVT was 9.6% (11). Thirty-six (55%) patients
were classified as high risk, 23 (35%) as moderate, and 7 (10%) as low risk. All patients diagnosed with DVT were in
the high-risk group (incidence, 16.7%). The sensitivity and negative predictive value were both 100% when PTP and
D-dimer were used, but fell to 80% and 95%, respectively, when only D-dimer was considered. The true negative rates
were 23% and 37%, respectively. Based on this study, we propose the following screening: for high-risk patients, use
direct VDI (no D-dimer); for low-risk or moderate-risk patients, obtain D-dimer, and if it is positive, use VDI, and if
it is negative, no further action is required. The average charge associated with the protocol was $170.50 as opposed
to $202.00 for global VDI.
Conclusion: A screening protocol using PTP along with selective D-dimer and VDI to exclude the diagnosis of DVT
among ED patients is efficacious and cost efficient. This screening approach establishes criteria to satisfy billing
requirements, can eliminate unnecessary VDI in 23% of ED referrals, and can reduce charges by 16%. (J Vasc Surg
2001;34:1010-5.)
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between April 1, 2000, and March 31, 2001, for VDI to
rule out thromboembolism. There were no ED patients
with suspected DVT who were excluded from the study.
The patient’s PTP for DVT was determined by the exam-
ining ED physician using a questionnaire developed by
Wells et al.6 Before initiating the study, all ED physicians
were trained on proper form completion. DVT risk was
established by total points received from evaluation of
nine clinical features (Table I). One point was given for
every positive finding and 2 points were subtracted if an
alternative diagnosis as likely as DVT was found. Patients
were then stratified into risk category according to total
points received, as follows: <0 points, low risk; 1 to 2
points, moderate risk; and >3 points, high risk. The valid-
ity and inter-rater reliability of this tool has been previ-
ously established.7-9
After completion of the PTP, D-dimer (SimpliRED)
was obtained. SimpliRED, a whole blood agglutination
assay, is based on the principle that agglutination of red
blood cells occurs in the presence of elevated D-dimer lev-
els.10 The presence of agglutination is visually determined.
Assays were routinely performed by trained technicians in
the hospital’s Center for Laboratory Medicine. As per
established guidelines, the threshold for a positive test
(point at which agglutination is visualized) was >200
µg/L.
VDI examinations were completed by registered tech-
nicians in a vascular laboratory accredited by the
Intersocietal Commission for the Accreditation of Vascular
Laboratories. The studies were completed using 7-MHz or
10-MHz probes on either Acuson 128xp/10v or Acuson
Aspen (Acuson Corporation, Mountain View, Calif). Both
legs were scanned from the iliac vein to the posterior tibial
and peroneal veins whenever possible. In addition, the
greater saphenous vein was routinely evaluated. DVT was
defined as visualization of thrombus and/or lack of com-
plete compressibility of the vein. Thrombus involving the
popliteal and proximal veins was classified as proximal
DVT. Serial VDI was not routinely performed to confirm
initial negative results. This practice has been described as
costly and inefficient. Wells et al5 found that only 1.3% of
patients with initial, negative VDI had a positive venogram
or positive VDI at 1-week testing. Furthermore, only 0.6%
had thromboembolic events during 3-month follow-up.
Correlation studies were completed using VDI as the
gold standard. The screening study was considered posi-
tive when the D-dimer was positive and/or the patient
was classified as high risk according to the PTP. The fol-
lowing screening algorithm was developed and evaluated:
global PTP; direct VDI for high-risk patients; D-dimer
for low-risk and moderate-risk patients, with selective
VDI for low-risk and moderate-risk patients having posi-
tive D-dimer results. Charges for VDI and SimpliRED
were obtained from the respective billing departments
because cost data were unavailable. and expenses associ-
ated with the above strategy were compared with those
for traditional DVT evaluation (global VDI).
RESULTS
One hundred fourteen patients were referred from
the ED to the vascular laboratory to evaluate DVT during
the study period. There were 86 (75%) women and 28
(25%) men. The mean age was 63 years (range, 19-92
years). The overall incidence of DVT was 9.6% (11
patients). Ten patients had proximal acute DVT. One
patient had an acute, proximal DVT in one leg and evi-
dence of chronic DVT in the other. There was only one
distal DVT involving the posterior tibial vein. In addition,
one patient had proximal DVT and superficial vein
thrombosis. Sixty-six (58%) patients had both PTP and
D-dimer completed, and 95 (83%) had D-dimer alone.
DVT risk classification and incidence of DVT per cate-
gory are presented in Table II. All the patients with DVT
who had both PTP and D-dimer completed were classi-
fied as high risk per PTP. There was one false-negative D-
dimer result within this group. Interestingly, there were
no DVTs among patients in the moderate-risk or low-risk
categories.
There were five DVTs among patients who did not
have both PTP and D-dimer completed before VDI. One
patient had no preselection testing, and four had only 
D-dimer completed. In this group, there was one false-
negative D-dimer result. However, upon retrospective
Table I. DVT pretest probability clinical features
Active cancer (treatment ongoing or within previous 6 months or palliative)
Paralysis, paresis, or recent plaster immobilization of the lower extremities
Recently bedridden for more than 3 days or major surgery within 4 weeks
Localized tenderness along the distribution of the deep venous system
Entire leg swollen
Calf swelling by >3 cm when compared with the asymptomatic leg (measured 10 cm below the tibial tuberosity)
Pitting edema (greater in the symptomatic leg)
Collateral superficial veins
Alternative diagnosis as likely as or more likely than DVT
Table II. Incidence of DVT by PTP risk classification
DVT risk classification n (%) Incidence of DVT
High risk (≥3 points) 36 (55) 6 (16.7)
Moderate risk (1-2 points) 23 (35) 0 (0)
Low risk (≤0 points) 7 (10) 0 (0)
Total 66 (100) 6 (9)
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review, all five patients would have been classified as high
risk per PTP.
Correlation studies were completed with VDI as the
gold standard. The combined screening approach of PTP
and D-dimer was compared with D-dimer alone. The
results are reported in Table III. The sensitivity and nega-
tive predictive values were both 100% when PTP and D-
dimer were used but fell to 80% and 95%, respectively, when
only D-dimer was considered. The true negative rates were
23% for D-dimer/PTP and 37% for D-dimer alone.
Charges for SimpliRED assay were $31.75 and
$202.00 for VDI. The proposed screening algorithm and
per patient charge are reported in Table IV. With this
strategy, 55% of patients fell into the high-risk category
and would have required direct VDI, which is the same as
traditional testing (global VDI). However, 23% of all
referrals were low-risk or moderate-risk patients with neg-
ative D-dimer results. The average per patient charge asso-
ciated with the protocol was 16% less than traditional
testing ($170.50 versus $202.00).
DISCUSSION
The clinical diagnosis of DVT is often unreliable with-
out objective testing.11,12 A dramatic increase in the use of
duplex sonography has occurred since its replacement of
venography as the gold standard to evaluate DVT.8,13,14
However, random use of VDI in patients with vague
symptoms suggestive of DVT not only burdens vascular
laboratories with large numbers of negative studies but
also contributes to increased health care costs. In addition,
Medicare and many other insurance companies have
recently imposed stringent reimbursement standards upon
vascular laboratories that mandate that objective indica-
tions for testing be documented.
Recently, the usefulness of the D-dimer assay as an
adjunct to the clinical examination to exclude the diagno-
sis of DVT has been evaluated. D-dimer, a product of fi-
brin degradation by plasmin, is generated in the presence
of thrombus. Therefore, the assay may be positive not only
in patients with DVT, but also in those who have under-
gone recent operation, sustained even minor trauma, or
have an active inflammatory process. However, the low
specificity (high false-positivity) of the examination is less
important, considering that the real value of the D-dimer
assay is in its ability to rule out the diagnosis of DVT.
There are four basic methods to measure D-dimer
concentration, latex agglutination, microplate ELISA,
membrane ELISA, and whole blood agglutination. The
advantages of the whole blood agglutination assay, as used
in this study, are that only a drop of whole blood is
required to complete the test, and results can be made
available within minutes. However, variability in test inter-
pretation can occur as a result of difficulty in distinguish-
ing weak positives from normal results, add-back
procedures in which blood is centrifuged and erythrocytes
are then added back at the time the assay is completed, or
if the sample is collected in citrated tubes verses capillary
stick.5,15,16 Because the sensitivities reported with
SimpliRED have ranged from 61% to 94%,4 caution
should be exercised when considering use of this assay as
the sole exclusionary preselection test for the evaluation of
DVT. In our study, the diagnosis of DVT would have been
missed in 20% of patients if only D-dimer assay was used.
The efficacy of the clinical model developed by Wells
et al (PTP) to predict probability of DVT has been evalu-
ated separately and in combination with other diagnostic
tools.6-9,17 As a single test, PTP sensitivity ranges from 8%
to 65%, specificity from 45% to 90%, PPV from 4% to 66%,
and negative predictive value from 62% to 89%. All vari-
ables except for negative predictive value significantly
increase in the group of patients classified as a high risk for
DVT.17 However, the variability of the sensitivity and neg-
ative predictive value between the different risk categories
limits the usefulness of PTP as a single exclusionary pre-
VDI selection test.
Several studies have focused on the use of combined
assessment schemes (PTP, D-dimer, and/or impedence
plethysmography) to eliminate unnecessary serial VDI 
Table III. PTP and D-dimer correlation study results
Screening test Sensitivity Specificity PPV Negative predictive value True negative rate
D-dimer alone 80% 41% 14% 95% 37%
D-dimer and PTP 100% 25% 12% 100% 23%
Table IV. Charges associated with DVT screening algorithm
Patient category Proposed strategy Incidence (%) Charge per pt
High-risk pts PTP, direct VDI 36 (55) $202.00
Low-risk and mod-risk pts with +D-dimer PTP, D-dimer, and VDI 15 (22.5) $233.75
Low-risk and mod-risk pts with –D-dimer PTP, D-dimer 15 (22.5) $31.75
All pts Per algorithm 66 (100) $170.50
pt, Patient; mod, moderate.
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 6 Dryjski et al 1013
follow-up exams. In contrast, we evaluated the usefulness
of PTP/D-dimer as an adjunctive preselection scheme to
be used before VDI is ordered. Our results are consistent
with other reports that a combined approach of PTP/D-
dimer can be used to successfully exclude the diagnosis of
DVT.8,17
In our study, all ED physicians were in-serviced on the
PTP. Therefore, form completion was not limited to one
trained physician, but rather was the responsibility of the
examining doctor. We felt that this was the most reason-
able approach, especially in light of the excellent inter-
rater reliability previously reported for the questionnaire.
SimpliRED was analyzed by trained technicians in our
clinical laboratory. However, hypothetically, it could have
been completed at the bedside by trained professionals
such as nurses, which could have potentially improved the
efficiency of our preselection strategy.
The overall incidence of DVT in this study was rather
low (9.6%), but did not differ significantly from findings
from the previous year (12%). This low incidence directly
reflects the large volume of negative VDI studies and enu-
merates the very reason we undertook this investigation.
We attribute the low incidence to a cautious approach by
ED physicians who, because of the relative insensitivity of
the physical examination to diagnose DVT, along with the
potentially devastating consequences of a missed diagno-
sis, are compelled to order VDI to exclude DVT. In addi-
tion, the incidence of DVT among high-risk patients was
only 16.7%, and there were no DVTs diagnosed in the
low-risk or moderate-risk groups. Again, this may reflect a
cautious approach by ED physicians who, for various rea-
sons, may have “overcoded” the PTP (ie, did not consider
alternative diagnoses as likely as DVT or reported swelling
that did not meet the criteria of the PTP). Thus, some of
the DVT patients may indeed have fallen into the moder-
ate-risk category. Although others have reported a signif-
icantly higher incidence of DVT (12%-23%) in the
moderate-risk category, the negative predictive value of
D-dimer within this group was 96.6%.2,18 Applying those
results to our own study, given the worse case scenario,
DVT would have gone undetected in 3.4% of moderate-
risk patients (1.2% of all patients).
We proposed the following algorithm for ED patients
with suspected DVT. PTP is completed for all patients.
High-risk patients receive direct VDI (without D-dimer
testing) because it is unlikely that a negative D-dimer
result in this category of patient would satisfy any clinician
that DVT could be safely excluded. D-dimer is obtained
for all moderate-risk and low-risk patients. No additional
testing is required for those with negative D-dimer results.
Those with positive D-dimer results undergo VDI.
In contrast to other authors, who have combined
moderate-risk patients with high-risk patients in their pre-
selection strategies, we grouped low-risk and moderate-
risk patients together. The rationale is that PTP allows for
identification of those patients who are at the highest risk
for false-negative results. Conversely, false-positive D-
dimer results will be highest in lower-risk patients. The
algorithm actually uses the low specificity (high false-
positive rate) of the D-dimer in low-risk and moderate-risk
patients as a safety mechanism. Unfortunately, only 58% of
our sample had combined PTP/D-dimer studies com-
pleted because of lack of attentiveness by ED physicians to
complete the PTP before VDI. Although 100% compli-
ance would have been ideal, it was noted on retrospective
review that each of the five DVT patients who did not
have both PTP and D-dimer studies completed would
have been classified as high risk for DVT. Although retro-
spective review can present bias, these findings provide
reassurance that the results of the study would remain
unchanged.
Using the algorithm, we calculated that VDI could
have been safely eliminated in 23% of referrals. Thus,
although this preselection scheme will not eliminate all
unnecessary VDI, it is likely to have a greater impact on
resource use than if only low-risk patients were elimi-
nated. However, we recommend that caution be exer-
cised when generalizing these results because of the small
sample size of the study.
CONCLUSIONS
A screening protocol using PTP along with selective
D-dimer and VDI to exclude the diagnosis of DVT
among ED patients is efficacious and cost efficient. This
diagnostic scheme can eliminate unnecessary VDI in a
substantial number of ED referrals and reduce costs con-
siderably. The PTP provides added assurance against false-
negative results that may occur at unacceptably high levels
when D-dimer is used alone. Furthermore, this screening
approach establishes criteria to satisfy billing requirements
that have become more stringent in recent years. Most
important, the protocol will have a positive impact on
resource use. PTP and some D-dimer assays can be com-
pleted at the bedside or D-dimer results made available
within minutes, making early diagnosis and streamlining
of care possible. This is of particular importance to hospi-
tals with busy EDs as well as to vascular laboratories that
perform many of these VDI studies during off hours,
which can be very costly to the laboratory.
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Dr Richard F. Neville (Washington, DC). Dr Ricotta, mem-
bers and guests. I appreciate the opportunity to discuss this paper.
As anybody who runs a vascular lab, or is affiliated with a vas-
cular lab, knows, diagnosis of deep venous thrombosis is a large
component of what we do. Many studies are ordered from our
emergency room and may seem to be inappropriate. We looked at
our experience at Georgetown over a 5-year period using a clini-
cal score assessment system. And it was interesting; we actually
found, using SVS-ISCVS scoring, that a number of our patients
who had DVTs and actually subsequently went on to have pul-
monary embolism, actually were classified as moderate and low
risk. So we also looked at some additional laboratory values,
including D-dimers, that we could utilize to help identify these
patients in a better manner. D-dimers are a new translational lab-
oratory value, and we are still gathering experience with that, but
we did notice that in our patients with DVT there was about
twice the normal, for our lab, value of D-dimer levels associated
with deep venous thrombosis.
The authors this morning tell us about 114 patients who
referred from their emergency room for venous imaging. Sixty-six
patients were scored clinically and had the D-dimer levels. There
were six DVTs in this group, and one of these DVTs was missed
by the D-dimer level. There were 95 patients which only had the
D-dimer levels performed. The authors demonstrated an average
cost savings of $30 per patient when they applied their protocol.
I have three questions for the authors.
There were only 58% of the patients, even though this was a
prospective trial, who were included and got both the clinical test-
ing and the D-dimers performed. Were there some inclusion or
exclusion criteria by your emergency room physicians why the entire
protocol wasn’t applied to all patients in a prospective manner?
The D-dimer assay actually had a fairly low sensitivity in this
study and missed 20% of the DVTs which were performed, and all
of the patients who had a DVT were scored as clinically high risk.
Do we need the D-dimer assay? Why can’t we obtain a venous
duplex on everyone who is clinically high risk?
I also noticed that there was a fairly low percentage of posi-
tive ultrasound studies referred from the ER. Maybe the ER
physicians are being overly aggressive with their referral patterns
and you should give them the clinical scoring system and have
them send the high-risk patients for DVT analysis.
We’re still using venous duplex fairly aggressively, but also inves-
tigating these types of helpful hints, including the use of D-dimers.
Thank you very much.
Dr Linda M. Harris. Thank you for your comments.
With regard to your first question, the reason that only 56%
of the patients had a PTP and D-dimer done wasn’t because of
exclusion, it was simply lack of efficiency, and not a concerted
effort to avoid the protocol, on the ER physician’s part. Some of
them get concerned that the patient has a DVT and they don’t
want to explore any new methods, they simply want to do what
they’ve always done in the past which is to send them for a duplex
study. We’re hopeful that with the information that we now have,
that they will utilize this protocol a little bit more completely.
We did look retrospectively by having the vascular laboratory
technicians do the PTP and that actually did not Change our
results. The patients who had DVTs all would have been high risk
in our group. We’d like to see the ER physicians do more of the
PTP and D-dimer and we’re working on that at this point in time.
Do we really need the D-dimer test? In our study, all the
patients who had DVT were in the high-risk group. However,
there have been other studies that have shown DVTs in the mod-
erate-risk group. We think that in our setting the ER physicians
probably tend to overcode. And that’s all right. We’d like to see
them code correctly, but they’re probably going to continue to
overcode to protect themselves. So if they have any concern, they
bump the patient up by a number. And that may be why all of our
patients who had DVTs were in the high-risk group. Over time if
some of those patients are coded into the moderate-risk group,
we would not want to miss a DVT by skipping the D-dimer. So
for that reason we continue to recommend the D-dimer for the
low- and moderate-risk patients.
And the last question, are too many patients sent to the vas-
cular laboratory? Probably, yes. ER physicians are concerned
about medical-legal issues. So if they have any question about a
deep vein thrombosis, they tend to send the patients to the vas-
cular laboratory thinking that it’s basically a cheap, painless test.
In the past they probably didn’t send as many patients because
venography was invasive; now that it’s an ultrasound, they do.
Dr John J. Ricotta (Stony Brook, NY). Linda, that was very
nice. Two questions.
First, if you used a different test other than the SimpliRed
with a higher negative predictive value, do you think that you
might be able to knock down the number of patients you’re send-
ing to the lab? If you’ve got to rely on the emergency room physi-
cians and they’ve decided they’re going to send everybody to the
lab, you’re going to send everybody to the lab. So I wonder
whether looking at the D-dimer in the high-risk group with a test
DISCUSSION
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that’s got a higher negative predictive value, using that in a more
discriminant way might be useful.
My second point is really a comment. I don’t know whether
it will work or not, but I think people that are having trouble get-
ting reimbursed for some of these tests, I think if you adopt this
PTP algorithm and can show that the patients that are being
studied have a clinical high risk, you may very well be more suc-
cessful in getting reimbursement.
Dr Harris. Thank you for your questions.
If we utilized one of the tests for D-dimer that had a higher
negative predictive value, we probably could decrease some of the
referrals. However, those tests take longer and cost more. So the
cost-benefit ratio will decrease. In other words, if you use a test
that costs $80, which some of the ELISA tests cost and take more
time, instead of the $30 test, you lose some of the benefit. We
would decrease the utilization of the vascular laboratory, but then
the cost for doing the combined tests would go up and we might
actually see a loss, economically, instead of a benefit over the stan-
dard routine of just sending the patient to the vascular laboratory.
For those two reasons, the cost and the time issue, we chose the
whole blood agglutination.
With regard to your second comment, I agree. I think that
this may help with reimbursement if we can show that the
patients are truly at high risk and truly actually have an indication.
Dr Anton N. Sidawy (Washington, DC). Dr Harris, what
do you think about the practice of giving the patient who comes
into the ER in the middle of the night a shot of subcutaneous
heparin and delaying the performance of lower-extremity
duplex study until the morning if an ultrasound tech is not
available at night?
Dr Harris. We actually don’t have the vascular lab open 24
hours a day. We’re open until 10 in the evening and then we close
overnight. So if a patient shows up at 2:00 in the morning with
isolated leg swelling, the ER docs either keep them there, give
them a shot of low molecular weight heparin and bring them
back the next morning, or admit the patient. The problem is even
though low molecular weight heparins are very safe, there is
some potential risk. And again, you hate to treat a patient who
doesn’t need to be treated.
Now, could you utilize this algorithm and say, the high-
risk patient probably should be treated and the lower, moder-
ate-risk patient probably doesn’t need to be treated and might
just have the study done later, which would be a reasonable
approach.
Dr Sidawy. What do you do on the weekend?
Dr Harris. On the weekend we also have the lab open from
8 am until 10 pm. We don’t think it’s reasonable for patient to
wait 24, 48 hours to have a venous duplex done.
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